ALDX - Aldeyra Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development13,175.677,574.3983,707.544
Selling General and Administrative5,520.3084,414.7093,563.046
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-18,695.978-11,989.107-7,270.59
Income from Continuing Operations
Total Other Income/Expenses Net102.03711.1262,327.505
Earnings Before Interest and Taxes-18,593.941-11,977.981-4,943.085
Interest Expense105.509112.306244.174
Income Before Tax-18,699.45-12,090.287-5,187.259
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-18,699.45-12,090.287-5,187.259
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-18,699.45-12,090.287-5,187.259
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-18,699.45-12,090.287-9,573.911